Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Cantor Fitzgerald
Johnson and Johnson
Boehringer Ingelheim

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,049,328

« Back to Dashboard

Which drugs does patent 7,049,328 protect, and when does it expire?

Patent 7,049,328 protects FERRIPROX and is included in two NDAs. There has been one Paragraph IV challenge on Ferriprox.

This patent has sixteen patent family members in fifteen countries.

Summary for Patent: 7,049,328

Title:Use for deferiprone
Abstract: A method of treating iron induced cardiac disease in a patient with iron overload, such as in thalassemia or the like comprising administering to the patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.
Inventor(s): Spino; Michael (Pickering, CA), Piga; Antonio (Moncalieri, IT)
Assignee: Apotex Inc. (Weston, CA)
Application Number:10/311,814
Patent Claim Types:
see list of patent claims
Use; Delivery; Composition; Dosage form; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Apopharma Inc
TABLET;ORAL021825-001Oct 14, 2011RXYesYes► Subscribe► Subscribe METHOD OF TREATING CHRONIC IRON OVERLOAD
Apopharma Inc
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,049,328

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Canada2313270Jun 30, 2000
PCT Information
PCT FiledJune 28, 2001PCT Application Number:PCT/CA01/00956
PCT Publication Date:January 10, 2002PCT Publication Number: WO02/02114

International Patent Family for Patent: 7,049,328

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel153733► Subscribe
Hong Kong1130422► Subscribe
Spain2324978► Subscribe
European Patent Office1294379► Subscribe
Denmark1294379► Subscribe
Germany60138189► Subscribe
Cyprus1109191► Subscribe
China101933924► Subscribe
China101380322► Subscribe
China1331971► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Army
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus